文献速递浆细胞疾病

卡非佐米联合地塞米松治疗新诊断多发性骨髓瘤的II期研究

Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma.
PubMed 文献 · Am J Hematol · 2019-02-25

这项单臂II期研究纳入72例新诊断多发性骨髓瘤患者,评估卡非佐米联合地塞米松诱导治疗的有效性和耐受性。卡非佐米分20/45 mg/m2(前25例)和20/56 mg/m2(后续47例)两个剂量队列。总体缓解率90%,≥非常好的部分缓解率65%,≥3级心血管不良事件发生率11.1%。

要点

  • 卡非佐米联合地塞米松诱导治疗新诊断多发性骨髓瘤的总体缓解率为90%。
  • 完全缓解或更好5例(7%),非常好的部分缓解42例(58%),部分缓解18例(25%),疾病稳定7例(10%)。
  • ≥3级心血管不良事件发生率为11.1%(8例事件),安全性特征与既往卡非佐米研究一致。

核心结论

  • 卡非佐米联合地塞米松在新诊断多发性骨髓瘤中表现出迄今报道的两药联合方案中最高的总体缓解率和≥非常好的部分缓解率。
  • 卡非佐米联合地塞米松的安全性特征与既往报道的卡非佐米研究一致。

研究设计与样本

  • 单臂II期研究,纳入72例新诊断多发性骨髓瘤患者,评估卡非佐米联合地塞米松诱导治疗的有效性和耐受性。
  • 卡非佐米分两个剂量队列给药:前25例为20/45 mg/m2,后续47例为20/56 mg/m2。
  • 卡非佐米在28天周期的第1、2、8、9、15、16天给药;地塞米松20 mg口服,在第1、2、8、9、15、16、22、23天给药。
  • 治疗持续至最大缓解、疾病进展或方案不可耐受;终点包括总体缓解率、方案毒性和卡非佐米对CD34+干细胞采集产量的影响。

主要发现

  • 65例患者达到至少部分缓解,总体缓解率为90%。
  • 最大缓解为完全缓解或更好5例(7%),非常好的部分缓解42例(58%),部分缓解18例(25%),疾病稳定7例(10%)。
  • 毒性以低级别为主,共547例1/2级不良事件和44例≥3级事件。
  • ≥3级心血管不良事件发生率为11.1%,观察到8例事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Carfilzomib and dexamethasone (Kd) has significant activity in relapsed and refractory multiple myeloma. Kd has not previously been evaluated in newly diagnosed multiple myeloma (NDMM). We report a single-arm phase 2 study of 72 patients with NDMM to evaluate the efficacy and tolerability of Kd induction. Carfilzomib was administered in two dosing cohorts with dosing of 20/45 mg/m2 in the first 25 patients and 20/56 mg/m2 in the subsequent 47 patients. Carfilzomib was administered on days 1, 2, 8, 9, 15 and 16 of a 28-day cycle, dexamethasone 20 mg was administered orally on days 1, 2, 8, 9, 15, 16, 22 and 23. Treatment was continued to maximum response, progression of disease, or regimen intolerability. Endpoints included overall response rate (ORR), regimen toxicity and impact of carfilzomib on CD34+ stem cell collection yield. Sixty-five pts achieved at least a partial response (PR) for an ORR of 90%. The maximum response achieved was complete response or better in 5 (7%), very good partial response (VGPR) in 42 (58%), PR in 18 (25%) and stable disease in 7 pts (10%). Toxicities were predominantly low grade with 547 grade 1/2 adverse events and 44 grade ≥3 events. The rate of grade ≥3 cardiovascular adverse events was 11.1% with eight observed events. The activity of Kd described represents the highest rate of overall response and ≥VGPR for any 2-agent combination in NDMM reported to date. Kd demonstrated a safety profile consistent with previously reported carfilzomib studies.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Forsberg PA, Rossi AC, Boyer A, et al. Phase II study of carfilzomib and dexamethasone therapy for newly diagnosed multiple myeloma. Am J Hematol. 2019. PMID: 30740766. doi:10.1002/ajh.25435

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。